20332-16-5

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Amino-1,3-benzodioxole-5-carboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure and properties allow it to be incorporated into the development of new drugs and therapies.
Used in Research Applications:
In the field of research, 6-Amino-1,3-benzodioxole-5-carboxylic acid serves as a valuable tool for studying the properties and mechanisms of benzodioxole derivatives. It can be used to investigate the potential pharmacological activities of this class of compounds and contribute to the advancement of drug discovery.
Used in Drug Development:
Due to its potential pharmacological activities, 6-Amino-1,3-benzodioxole-5-carboxylic acid is used in the development of drugs and therapies. Its unique chemical properties and high solubility in water make it a promising candidate for the creation of new medicinal agents.
Used in Chemical Industry:
6-Amino-1,3-benzodioxole-5-carboxylic acid is also utilized in the chemical industry for the synthesis of various organic compounds and materials. Its versatility and stability make it a valuable component in the production of specialty chemicals and intermediates.

InChI:InChI=1/C8H7NO4/c9-5-2-7-6(12-3-13-7)1-4(5)8(10)11/h1-2H,3,9H2,(H,10,11)

Upstream product

• 716-32-5 6-nitrobenzo[d][1,3]dioxole-5-carboxylic acid 
• 721-00-6 methyl 6-nitrobenzo[d][1,3]dioxole-5-carboxylate 
• 267-54-9 3-methyl[1,3]dioxolo[4’,5’:4,5]benzisoxazoleb 
• 7647-01-0 hydrogenchloride 
• 23126-68-3 6-amino-benzo[1,3]dioxole-5-carbaldehyde 
• 120-57-0 piperonal 
• 712-97-0 6-nitro-1,3-benzodioxole-5-carbaldehyde 
• 94-53-1 Piperonylic acid 
• 40680-63-5 methyl 6-aminobenzo[d][1,3]dioxole-5-carboxylate 
• 326-56-7 methyl 3,4-methylenedioxybenzoate 

Downstream Products

• 848474-61-3 6-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-benzo[1,3]dioxole-5-carboxylic acid 
• 548-31-2 oxynitidine 
• 34060-22-5 N-methyl-3,4-(methylenedioxy)aniline 
• 28857-37-6 (6-aminobenzo[d][1,3]dioxol-5-yl)methanol 
• 886493-57-8 C₁₅H₁₅NO₅S 
• 20197-55-1 6,8-dichloro-2H-[1,3]dioxolo[4,5-g]quinazoline 

Relevant academic research and scientific papers

As the PI3K/mTOR inhibitor tricyclic compound, its preparation and use

The invention discloses a tricyclic compound as a PI3K/mTOR inhibitor. The tricyclic compound is a compound with the general formula (I) in the specification, wherein Ar is selected from aryl or heteroaryl; X, Y and Z are independently selected from O, CR2R3 and NR4 respectively; Q is selected from O, CR2R3 and NR4 or does not exists; R1 represents C1-C6 alkyl; n is selected from integers from 0 to 4; when n is more than or equal to 2, two R1 and a morpholine cycle can be combined into a combined cycle, a bridge cycle or a spiral cycle; R2 and R3 are selected from hydrogen and C1-C6 alkyl; R4 is selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, heterocyclic radical, acyl and sulfonyl. The invention further discloses a perpetration method of the compound with the general formula (I) as well as a pharmaceutical composition and application of the compound with the general formula (I).

Condensation of anthranilic acids with pyridines to furnish pyridoquinazolones via pyridine dearomatization

The unprecedented carbodiimide-mediated condensation between pyridines and anthranilic acids via pyridine dearomatization at room temperature has been developed to provide a straightforward approach to pyridoquinazolones. The value of this approach has further been demonstrated by its application to one-step, gram-scale syntheses of a series of pyridoquinazolone-based natural products and their analogues from readily available starting materials.

Synthesis and structure-activity relationships of vasicine analogues as bronchodilatory agents

The series of vasicine (1) analogues, an alkaloid from Adhatoda vasica Nees., were synthesized with changes in A, B or C rings. Compounds 3-19 were evaluated for in vitro bronchodilatory activity using isolated guinea pig tracheal chain. Compounds 3-8 were also synthesized in good yields using microwave-mediated synthesis under solvent free conditions. Compounds 5 and 8 with seven-member C ring were more active than etofylline and caused 100% relaxation of both the histamine and acetylcholine pre-contracted guinea pig tracheal chain. The structure-activity relationship studies showed that the quinazoline and oxo functionalities were essential for activity. The compounds without C ring and instead having aliphatic and phenyl substitutions in B ring showed relaxation against histamine pre-contracted tracheal chain only, 2-methyl substituted analogues, 12 and 13, being most active with 100% relaxation effect. Birkhaeuser Boston 2006.

FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF

AbstractNovel compounds of the following formula (I) and pharmacologically acceptable salt and esters thereof can modulate LXR function and as a result show excellent anti-arteriosclerotic and anti-inflammatory activity:wherein:A represents aryl or heteroaryl;R1, R2 and R3 are the same or different and each represents hydrogen, hydroxyl, nitro, cyano, amino, halogen, carboxy, carbamoyl, mercapto, alkyl, haloalkyl, alkylcarbonyloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, dialkylamino, alkylcarbonylamino, N-(alkylcarbonyl)-N-(alkyl)amino, alkoxycarbonylamino, N-(alkoxycarbonyl)-N-(alkyl)amino, alkylsulfonylamino, N-(alkylsulfonyl)-N-(alkyl)amino, haloalkylsulfonylamino, N-(haloalkylsulfonyl)-N-(alkyl)amino, alkylcarbonyl, alkoxycarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or R1 and R2 together are alkylenedioxy;R4 and R5 are the same or different and each represents hydrogen, hydroxyl, amino, halogen, mercapto, alkyl, haloalkyl, alkoxy, alkoxycarbonyl or alkylthio;X represents hydrogen, hydroxyl, halogen, alkoxy or haloalkoxy; andY represents an optionally substituted alkyl, cycloalkyl, heterocyclyl, aryl, cycloalkylalkyl, heterocyclylalkyl or aralkyl group.

Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases

The present invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts thereof, wherein R1-R4and Z are as defined herein. The compounds of formula (I) are useful as antiproliferative agents. The invent